Trial NCT04756323, ChiCTR2000039462
Publication Pan HX, Chin Med J, 2021
Primary outcome on the report: Neutralization antibody seroconversion and RBD-IgG seroconversion at 28 days after administration of the second dose

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.